← Leaderboards
Brenda Marie Sandmaier
Fred Hutchinson Cancer Research Center
$22,185,663
Attributed
$22,567,313
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,760,189 · 18
By mechanism
P01$38,032,774 · 14
R01$4,655,359 · 2
R33$1,580,297 · 1
R21$491,759 · 1
Top collaborators
- Rainer F. Storb16 shared
- John M. Pagel1 shared
- Roland Bruno Walter1 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Rainer F. Storb$23,835,935
- John M. Pagel$5,647,981
- Lauri M. Burroughs$850,274
- George Earl Georges$15,152,269
- Oliver W. Press$23,607,906
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicDoseLabelMonoclonal AntibodiesRadioisotopesAstatineTransplantationRegimenWhole-Body IrradiationConditioningHematopoieticPtprc GeneAllograftingBaseMalignant NeoplasmsRelapsePre-ClinicalToxic EffectHematopoietic Cell TransplantationCanis FamiliarisDysmyelopoietic SyndromesSuccessFludarabineGrant
Grant awards (83)
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$2,074,913
P01 · FY2025 · CA · contact PI
Core B: Pharmaceutical Production$681,869
P01 · FY2025 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$283,800
P01 · FY2025 · CA · contact PI
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$2,074,913
P01 · FY2023 · CA · contact PI
Core B: Pharmaceutical Production$479,461
P01 · FY2023 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$331,595
P01 · FY2023 · CA · contact PI
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$2,071,892
P01 · FY2022 · CA · contact PI
Core B: Pharmaceutical Production$465,370
P01 · FY2022 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$337,761
P01 · FY2022 · CA · contact PI
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$1,449,399
P01 · FY2021 · CA · contact PI
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$679,409
P01 · FY2021 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$515,540
P01 · FY2021 · CA · contact PI
Core B: Pharmaceutical Production$479,464
P01 · FY2021 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$241,565
P01 · FY2021 · CA · contact PI
Core B: Pharmaceutical Production$241,565
P01 · FY2021 · CA · contact PI
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$1,846,796
P01 · FY2020 · CA · contact PI
Core B: Pharmaceutical Production$490,543
P01 · FY2020 · CA · contact PI
Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome$314,570
P01 · FY2020 · CA · contact PI
Hematopoietic Chimerism after Stem Cell Allografts$984,084
P01 · FY2019 · CA
Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha Radiation$486,199
P01 · FY2019 · HL · contact PI
Hematopoietic Chimerism after Stem Cell Allografts$892,086
P01 · FY2018 · CA
Alpha Radioimmunotherapy for Lymphoma Treatment$503,673
R01 · FY2018 · CA · contact PI
Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha Radiation$487,791
P01 · FY2018 · HL · contact PI
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$346,370
R33 · FY2018 · AI · contact PI
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$173,480
R33 · FY2018 · AI · contact PI
Alpha Radioimmunotherapy for Lymphoma Treatment$131,173
R01 · FY2018 · CA · contact PI
Project 2: Stem Cell Allografts for Acute Leukemia and Myelodysplasia$114,301
P01 · FY2018 · CA · contact PI
Program Integration and management$8,886
P01 · FY2018 · CA
Hematopoietic Chimerism after Stem Cell Allografts$2,023,730
P01 · FY2017 · CA
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$520,913
R33 · FY2017 · AI · contact PI
Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha Radiation$490,945
P01 · FY2017 · HL · contact PI
Project 2: Stem Cell Allografts for Acute Leukemia and Myelodysplasia$239,833
P01 · FY2017 · CA · contact PI
Program Integration and management$18,647
P01 · FY2017 · CA
Hematopoietic Chimerism after Stem Cell Allografts$2,023,730
P01 · FY2016 · CA
Alpha Radioimmunotherapy for Lymphoma Treatment$634,846
R01 · FY2016 · CA · contact PI
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$539,534
R33 · FY2016 · AI · contact PI
Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha Radiation$492,537
P01 · FY2016 · HL · contact PI
Project 2: Stem Cell Allografts for Acute Leukemia and Myelodysplasia$239,833
P01 · FY2016 · CA · contact PI
Program Integration and management$18,647
P01 · FY2016 · CA
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,206,479
P01 · FY2015 · CA · contact PI
Hematopoietic Chimerism after Stem Cell Allografts$2,019,079
P01 · FY2015 · CA
Alpha Radioimmunotherapy for Lymphoma Treatment$634,846
R01 · FY2015 · CA · contact PI
Project 2: Minimal-Intensity Conditioning with Antibody-Targeted Alpha Radiation$495,232
P01 · FY2015 · HL · contact PI
Project 2: Stem Cell Allografts for Acute Leukemia and Myelodysplasia$239,833
P01 · FY2015 · CA · contact PI
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$235,160
R21 · FY2015 · AI · contact PI
Program Integration and management$18,647
P01 · FY2015 · CA
Hematopoietic Chimerism after Stem Cell Allografts$1,846,366
P01 · FY2014 · CA
Alpha Radioimmunotherapy for Lymphoma Treatment$640,365
R01 · FY2014 · CA · contact PI
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells$256,599
R21 · FY2014 · AI · contact PI
Project 2: Stem Cell Allografts for Acute Leukemia and Myelodysplasia$153,120
P01 · FY2014 · CA · contact PI
Program Integration and management$19,085
P01 · FY2014 · CA
Alpha Radioimmunotherapy for Lymphoma Treatment$679,389
R01 · FY2013 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations$191,230
P01 · FY2013 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations$197,643
P01 · FY2012 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations$199,973
P01 · FY2011 · CA · contact PI
Core--Protocol Management and Coordination of Multi-center Trials$536,587
P01 · FY2010 · HL · contact PI
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD$419,118
P01 · FY2010 · HL · contact PI
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts$285,649
R01 · FY2010 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations$200,914
P01 · FY2010 · CA · contact PI
Core--Protocol Management and Coordination of Multi-center Trials$522,323
P01 · FY2009 · HL · contact PI
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD$409,105
P01 · FY2009 · HL · contact PI
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts$286,015
R01 · FY2009 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations$240,449
P01 · FY2009 · CA · contact PI
Core--Protocol Management and Coordination of Multi-center Trials$498,650
P01 · FY2008 · HL · contact PI
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD$391,672
P01 · FY2008 · HL · contact PI
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts$286,369
R01 · FY2008 · CA · contact PI
Mixed Chimerism in the Treatment of Leukemias$222,234
P01 · FY2008 · CA · contact PI
Core--Protocol Management and Coordination of Multi-center Trials$526,368
P01 · FY2007 · HL · contact PI
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD$414,643
P01 · FY2007 · HL · contact PI
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts$273,434
R01 · FY2007 · CA · contact PI
Mixed Chimerism in the Treatment of Leukemias$220,199
P01 · FY2007 · CA · contact PI
Core--Protocol Management and Coordination of Multi-center Trials$509,409
P01 · FY2006 · HL · contact PI
Nonmyeloablative Allografts in DLA-haploidentical Dogs:$401,715
P01 · FY2006 · HL · contact PI
Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts$299,600
R01 · FY2006 · CA · contact PI
Mixed Chimerism in the Treatment of Leukemias$117,722
P01 · FY2006 · CA · contact PI
Nonmyeloablative grafts in littermate dogs$210,244
P01 · FY2005 · HL
Mixed Chimerism in the Treatment of Leukemias$114,293
P01 · FY2005 · CA
Nonmyeloablative grafts in littermate dogs$205,452
P01 · FY2004 · HL
Mixed Chimerism in the Treatment of Leukemias$110,964
P01 · FY2004 · CA
NONMYELOABLATIVE GRAFTS IN LITTERMATES$416,641
P01 · FY2003 · HL
NONMYELOABLATIVE GRAFTS IN LITTERMATES$0
P01 · FY2002 · HL
NONMYELOABLATIVE GRAFTS IN LITTERMATES$0
P01 · FY2001 · HL
NOMYELOABLATIVE CONDITIONING REGIMENS--MIXED CHIMERISM$175,711
P01 · FY2000 · HL